Please login to the form below

Not currently logged in
Email:
Password:

aTyr appoints rare disease expert as president

Frederic Chereau has senior experience at Shire and Genzyme

US-based firm aTyr Pharma has appointed Frederic Chereau as president and chief operating officer to support the advance of its portfolio of medicines for rare diseases.

Chereau has significant experience in the field, working at rare disease specialist Genzyme from 1999 to 2008, eventually becoming president and general manager of the company's cardiovascular business.

He was later president and CEO of Pervasis Therapeutics, which was acquired by Shire in 2012.

Dr John Mendlein, CEO and executive chairman of aTyr Pharma, said that Chereau's appointment will guide the company's “global outreach and strategic partnerships”.

7th February 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics